[go: up one dir, main page]

BR9506924A - Sublingual or oral pharmaceutical composition and use of trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1h-dibenz (2,3: 6,7) oxepine (4,5-c) pyrrole - Google Patents

Sublingual or oral pharmaceutical composition and use of trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1h-dibenz (2,3: 6,7) oxepine (4,5-c) pyrrole

Info

Publication number
BR9506924A
BR9506924A BR9506924A BR9506924A BR9506924A BR 9506924 A BR9506924 A BR 9506924A BR 9506924 A BR9506924 A BR 9506924A BR 9506924 A BR9506924 A BR 9506924A BR 9506924 A BR9506924 A BR 9506924A
Authority
BR
Brazil
Prior art keywords
sublingual
pharmaceutical composition
dibenz
pyrrole
tetrahydro
Prior art date
Application number
BR9506924A
Other languages
Portuguese (pt)
Inventor
Leonardus Petrus C Delbressine
Johannes Hubertus Wieringa
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9506924(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR9506924A publication Critical patent/BR9506924A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PCT No. PCT/EP95/00765 Sec. 371 Date Oct. 11, 1996 Sec. 102(e) Date Oct. 11, 1996 PCT Filed Mar. 1, 1995 PCT Pub. No. WO95/23600 PCT Pub. Date Sep. 8, 1995The invention relates to a sublingual or buccal pharmaceutical composition comprising trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrole or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable auxiliaries suitable for use in sublingual or buccal compositions, and the use thereof for the manufacture of a sublingual or buccal pharmaceutical composition for the treatment of mental disorders, such as psychosis and schizophrenia.
BR9506924A 1994-03-02 1995-03-01 Sublingual or oral pharmaceutical composition and use of trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1h-dibenz (2,3: 6,7) oxepine (4,5-c) pyrrole BR9506924A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94200521 1994-03-02
PCT/EP1995/000765 WO1995023600A1 (en) 1994-03-02 1995-03-01 Sublingual or buccal pharmaceutical composition

Publications (1)

Publication Number Publication Date
BR9506924A true BR9506924A (en) 1997-09-30

Family

ID=8216678

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9506924A BR9506924A (en) 1994-03-02 1995-03-01 Sublingual or oral pharmaceutical composition and use of trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1h-dibenz (2,3: 6,7) oxepine (4,5-c) pyrrole
BR1100625-0A BR1100625A (en) 1994-03-02 1997-05-13 Sublingual or oral pharmaceutical composition, and, use of trans-5-chloro-2-methyl-2,3,3a, 12b-tetraido-1h-dibenz [2,3: 6,7] oxepine [4,5-c] pyrrole

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR1100625-0A BR1100625A (en) 1994-03-02 1997-05-13 Sublingual or oral pharmaceutical composition, and, use of trans-5-chloro-2-methyl-2,3,3a, 12b-tetraido-1h-dibenz [2,3: 6,7] oxepine [4,5-c] pyrrole

Country Status (23)

Country Link
US (1) US5763476A (en)
EP (1) EP0746317B1 (en)
JP (2) JP4099224B2 (en)
KR (1) KR100330942B1 (en)
CN (1) CN1079670C (en)
AT (1) ATE167057T1 (en)
AU (1) AU692530B2 (en)
BR (2) BR9506924A (en)
CA (1) CA2182981C (en)
CZ (1) CZ284633B6 (en)
DE (2) DE69502939T2 (en)
DK (1) DK0746317T3 (en)
ES (1) ES2118584T3 (en)
FI (1) FI117923B (en)
FR (1) FR10C0056I2 (en)
HK (1) HK1008417A1 (en)
HU (1) HU225051B1 (en)
LU (1) LU91751I2 (en)
NO (2) NO308772B1 (en)
NZ (1) NZ282394A (en)
PL (1) PL180465B1 (en)
RU (1) RU2139051C1 (en)
WO (1) WO1995023600A1 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032108A1 (en) * 1997-12-19 1999-07-01 Akzo Nobel N.V. Org-5222 in the treatment of depression
CA2476250C (en) * 2002-02-13 2010-08-03 Michael K. Weibel Drug dose-form and method of manufacture
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
MXPA05012317A (en) * 2003-05-16 2006-01-30 Pfizer Prod Inc Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines.
TWI327915B (en) * 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight
EP1753460A2 (en) * 2004-05-11 2007-02-21 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
GB0416861D0 (en) * 2004-07-29 2004-09-01 Quadrant Drug Delivery Ltd Composition
RU2403039C2 (en) * 2004-10-15 2010-11-10 H.B.Opганон Treatment of bipolar disorders and accompanying symptoms
KR101422843B1 (en) * 2005-04-07 2014-07-24 머크 샤프 앤 도메 비.브이. Crystal form of asenapine maleate
US7872147B2 (en) 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
DE602006010132D1 (en) 2005-04-07 2009-12-17 Organon Nv Intermediates for the preparation of trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1h-dibenzE2,3: 6,7O-oxo-amino-4,5-cpyrrole
US7741358B2 (en) * 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
US7750167B2 (en) 2006-07-05 2010-07-06 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
US7875729B2 (en) 2007-01-05 2011-01-25 Synthon Bv Process for making asenapine
PE20091156A1 (en) * 2007-12-17 2009-09-03 Astrazeneca Ab SALTS OF (3 - {[[3- (6-AMINO-2-BUTOXY-8-OXO-7,8-DIHIDRO-9H-PURIN-9-IL) PROPYL] (3-MORFOLIN-4-ILPROPIL) AMINO] METHYL} PHENYL) METHYL ACETATE
CA2727573A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
WO2010127674A1 (en) * 2009-05-06 2010-11-11 Sunin K/S Transdermal compositions of asenapine for the treatment of psychiatric disorders
BRPI1011453A2 (en) 2009-06-24 2016-03-15 Msd Oss Bv formulation, dosage form of a drug, and asenapine hemipamoate salt
AR077429A1 (en) 2009-07-29 2011-08-24 Organon Nv HYDROXIASENAPINA COMPOUNDS ITS DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE SAME
CA2802990A1 (en) 2010-06-18 2011-12-22 Dr. Reddy's Laboratories Ltd. Asenapine maleate
JP5815702B2 (en) 2010-07-29 2015-11-17 ラボラトリオス レスヴィ，エス．エル． A novel method for manufacturing asenapine
WO2012038975A2 (en) * 2010-09-22 2012-03-29 Msn Laboratories Limited Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof
NO3034079T3 (en) 2010-11-15 2018-06-09
WO2012066565A2 (en) 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
EP2524919A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
EP2709615A1 (en) 2011-05-18 2014-03-26 Laboratorios Lesvi, S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
US9505771B2 (en) * 2011-05-18 2016-11-29 Laboratories Lesvi S.L. Stable micronised monoclin form of asenapine maleate and its synthesis
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
CN102657635B (en) * 2012-05-04 2013-08-07 上海现代药物制剂工程研究中心有限公司 Spongy asenapine sublingual film agent with micropores and preparation method thereof
ITMI20121810A1 (en) 2012-10-24 2014-04-25 Chemo Iberica Sa POLISHED ASHENAPINE POLYPHORMS AND PROCESS FOR THEIR PREPARATION
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9597291B2 (en) 2012-12-11 2017-03-21 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
CA3053189A1 (en) 2012-12-20 2014-06-26 Kashiv Biosciences, Llc Orally disintegrating tablet formulation for enhanced bioavailability
CN103893139B (en) * 2012-12-28 2018-06-08 石药集团中奇制药技术（石家庄）有限公司 A kind of asenapine composition and preparation method thereof
CN103120688A (en) * 2013-01-11 2013-05-29 盛世泰科生物医药技术(苏州)有限公司 Pharmaceutical composition of flash release preparation
WO2014116770A1 (en) * 2013-01-23 2014-07-31 Arx, Llc Production of unit dose constructs
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
IN2013MU02206A (en) * 2013-06-28 2015-06-12 Alembic Pharmaceuticals Ltd
AU2014368961B2 (en) 2013-12-20 2019-10-17 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2015125152A2 (en) * 2014-02-18 2015-08-27 Hetero Research Foundation Pharmaceutical compositions of asenapine
HUE065482T2 (en) 2014-04-04 2024-05-28 Intra Cellular Therapies Inc Deuterated heterocycle fused gamma-carbolines as antagonists of 5-ht2a receptors
TR201509009A1 (en) * 2014-12-11 2017-02-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A thin film strip of asenapine
WO2016198113A1 (en) 2015-06-11 2016-12-15 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
WO2016205739A1 (en) 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
PT3407888T (en) 2016-01-26 2021-03-19 Intra Cellular Therapies Inc PYRIDOPIRROLOQUINOXALIN COMPOUNDS, THEIR COMPOSITIONS AND USES
EP3407889B1 (en) 2016-03-25 2021-05-19 Intra-Cellular Therapies, Inc. Organic compounds and their use in treating or preventing central nervous system disorders
US10085971B2 (en) 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
ES2769286T3 (en) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
MX2019011329A (en) 2017-03-24 2019-12-02 Intra Celular Therapies Inc Novel compositions and methods.
ES2881783T3 (en) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic polymer
CA3094204A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
WO2019246300A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX2020014286A (en) 2018-06-20 2021-03-25 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine.
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
US11957791B2 (en) 2018-08-31 2024-04-16 Intra-Cellular Therapies, Inc. Methods
CN118873536A (en) 2018-08-31 2024-11-01 细胞内治疗公司 New approach
EP3993798A4 (en) 2019-07-07 2023-04-26 Intra-Cellular Therapies, Inc. NEW PROCESSES
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (en) * 1976-05-24 1977-11-28 Akzo Nv NEW TETRACYCLICAL DERIVATIVES.
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
FR2480283A1 (en) * 1980-04-10 1981-10-16 Science Union & Cie NOVEL TRICYCLIC DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS A MEDICINAL PRODUCT
JPS5967218A (en) * 1982-10-07 1984-04-16 Grelan Pharmaceut Co Ltd soft oral preparation
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
CA2027243A1 (en) * 1989-10-17 1991-04-18 Everett H. Ellinwood, Jr. Intraoral formulated trifluorobenzodiazepines and the use thereof
US5496559A (en) * 1991-04-08 1996-03-05 Sumitomo Pharmaceuticals Company, Limited Porous solid formulations containing proteinaceous physiologically active substances
CA2095499A1 (en) * 1992-05-08 1993-11-09 Petrus J. M. Van Den Oetelaar Depot preparation
EP0569096A1 (en) * 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation

Also Published As

Publication number Publication date
FR10C0056I2 (en) 2011-11-25
NO308772B1 (en) 2000-10-30
DE69502939T2 (en) 1998-10-22
DE122010000050I2 (en) 2011-07-21
HK1008417A1 (en) 1999-05-07
CN1143320A (en) 1997-02-19
KR100330942B1 (en) 2002-11-16
CZ284633B6 (en) 1999-01-13
JP4616810B2 (en) 2011-01-19
PL180465B1 (en) 2001-02-28
BR1100625A (en) 1999-12-28
EP0746317B1 (en) 1998-06-10
CN1079670C (en) 2002-02-27
NO2010024I2 (en) 2012-04-10
NZ282394A (en) 1997-12-19
ES2118584T3 (en) 1998-09-16
AU1947895A (en) 1995-09-18
RU2139051C1 (en) 1999-10-10
LU91751I2 (en) 2011-01-04
FI963398L (en) 1996-08-30
NO963639D0 (en) 1996-08-30
FI117923B (en) 2007-04-30
JP4099224B2 (en) 2008-06-11
CA2182981C (en) 2006-10-17
DK0746317T3 (en) 1999-03-22
DE69502939D1 (en) 1998-07-16
DE122010000050I1 (en) 2011-05-05
JP2006342178A (en) 2006-12-21
NO963639L (en) 1996-10-30
MX9603713A (en) 1997-12-31
HU9602383D0 (en) 1996-10-28
ATE167057T1 (en) 1998-06-15
US5763476A (en) 1998-06-09
FR10C0056I1 (en) 2011-01-28
CA2182981A1 (en) 1995-09-08
JPH09509674A (en) 1997-09-30
FI963398A0 (en) 1996-08-30
EP0746317A1 (en) 1996-12-11
CZ254196A3 (en) 1997-10-15
NO2010024I1 (en) 2011-01-03
PL316080A1 (en) 1996-12-23
HU225051B1 (en) 2006-05-29
AU692530B2 (en) 1998-06-11
WO1995023600A1 (en) 1995-09-08
HUT76319A (en) 1997-08-28

Similar Documents

Publication Publication Date Title
BR1100625A (en) Sublingual or oral pharmaceutical composition, and, use of trans-5-chloro-2-methyl-2,3,3a, 12b-tetraido-1h-dibenz [2,3: 6,7] oxepine [4,5-c] pyrrole
AUPR213700A0 (en) Antiviral agents
CA2293823A1 (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
UA70298A (en) Derivatives of с-4"-substituted macrolides
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
NZ284846A (en) 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
RU96120090A (en) SUBLINGUAL OR TRANSBUKCAL PHARMACEUTICAL COMPOSITION
AU3563695A (en) Novel piperidine derivatives with paf antagonist activity
EE03262B1 (en) Alkoxyalkylcarbamates from Imidazo [1,2-a] pyridines, their Preparation and Use
NZ320355A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
HK1011527A1 (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
IL115004A (en) Pharmaceutical compositions containing substituted 6-amino-4H-pyrans certain novel such compounds and their preparation
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
MY135855A (en) "pyrrolopyrimidinone derivatives, process of preparation and use"

Legal Events

Date Code Title Description
FA Application withdrawn